H.R. 6626: PFAS Accountability Act of 2025
The bill known as the PFAS Accountability Act of 2025 aims to address public health concerns related to per- and polyfluoroalkyl substances (PFAS), often referred to as "forever chemicals" due to their persistence in the environment and the human body. This legislation proposes several key actions:
Key Findings
- PFAS have been detected in the blood of individuals across the United States, as identified by the Centers for Disease Control and Prevention (CDC).
- Studies indicate that PFAS are present in the drinking water of millions of people.
- Research into the safety of PFAS remains limited despite their continued introduction into the market.
- Currently, a federal legal remedy does not exist for individuals suffering from health effects related to PFAS exposure.
- PFAS exposure is linked to chronic diseases such as cancer and detrimental impacts on reproductive and immune systems.
Legislative Purposes
The legislation aims to:
- Encourage research and ensure accountability in PFAS manufacturing by establishing a federal cause of action for individuals exposed to these substances.
- Facilitate access to medical monitoring as a remedy for those affected.
- Legally recognize the harm from PFAS exposure and shift the financial burden of medical monitoring from individuals to the responsible parties.
- Incentivize industries to fund safety research related to PFAS.
Legal Provisions
The bill seeks to amend the Toxic Substances Control Act to establish legal measures regarding PFAS:
- Cause of Action: Individuals significantly exposed to PFAS can claim legal and equitable relief against manufacturers or users of PFAS, particularly if they should have anticipated human exposure during production.
- Medical Monitoring:
- Court-awarded medical monitoring for those showing increased health risks due to exposure.
- Individuals presumed to be significantly exposed if they can show a link to manufacturing processes and that PFAS were released in their vicinity.
- Class Actions: Those harmed can bring collective legal action if they share common exposure characteristics, easing the burden of proof on individuals.
- Rebutting Presumptions: Defendants may challenge claims of exposure but must cover associated testing costs.
- Scientific Proof: Courts can adjust standards for proving health risks when data is insufficient and can order studies to gather more information.
Impact on State Law
The act would not interfere with state law claims or remedies concerning PFAS, allowing individuals to pursue legal actions at the state level in addition to those available federally.
Relevant Companies
- DOW - Dow Inc. is involved in the manufacture of chemicals, including PFAS substances. This legislation could lead to increased scrutiny and potential liabilities relating to PFAS exposure from their products.
- EMN - Eastman Chemical Company also produces PFAS, and this legislation may increase costs related to compliance and potential litigation from exposure claims.
- MON - Corteva, Inc. (formerly part of DowDuPont) engages in agricultural products that may include PFAS. This act may impact their manufacturing practices and liability regarding environmental and health effects.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
5 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Dec. 11, 2025 | Introduced in House |
| Dec. 11, 2025 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
